Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRB1 | P18505 | 1/20 | 0.52 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.52 |
| ▸ | GPR88 | Q9GZN0 | 2/20 | 0.51 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | CTSK | P43235 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 1/20 | 0.49 |
| ▸ | UTS2R | Q9UKP6 | 5/20 | 0.44 |
| ▸ | MMP9 | P14780 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | ACACB | O00763 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5676217 | 1.00 | GABRB1 (0.52) | GABRB1GABRB2GPR88CTSSCTSK | |
| SCHEMBL9295219 | 0.90 | GABRB1 (0.50) | GABRB1GABRB2CTSSCTSKCTSB | |
| SCHEMBL5676053 | 0.88 | ABCB11 (0.49) | GPR88CYP1A2TSHR | |
| SCHEMBL21715586 | 0.88 | GABRB1 (0.48) | GABRB1GABRB2CTSSCTSKCTSB | |
| SCHEMBL5870754 | 0.88 | ABCB11 (0.49) | GPR88CYP1A2TSHR | |
| SCHEMBL13802924 | 0.87 | GABRB1 (0.53) | GABRB1GABRB2CTSSCTSKCTSB | |
| SCHEMBL8362256 | 0.86 | GABRB1 (0.52) | GABRB1GABRB2CTSSCTSKCTSB | |
| SCHEMBL7299702 | 0.86 | GABRB1 (0.49) | GABRB1GABRB2GPR88CTSSCTSK | |
| SCHEMBL5870652 | 0.84 | GABRB1 (0.49) | GABRB1GABRB2CTSSCTSKCTSB | |
| SCHEMBL5870653 | 0.84 | GABRB1 (0.49) | GABRB1GABRB2CTSSCTSKCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7144881-B2 | Arylcyclopropylcarboxylic amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| US-7045551-B2 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-05-16 | — | — | US | disclosed |
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-24 | — | — | US | disclosed |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | BRISTOL-MYERS SQUIBB COMPANY | 2004-06-10 | — | — | US | disclosed |
| EP-0161801-A2 | Perhydrothiazepine derivatives, their preparation and their therapeutic use | SANKYO COMPANY LIMITED (JP) | 1985-11-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122007-A1 | 1-aryl-2-hydroxyethyl amides as potassium channel openers | KCNQ3, KCNQ2, KCNQ4 | GABRB1 190/4885GABRB2 205/4885GPR88 429/4885 |
| US-20040110754-A1 | 2-(2-fluoro-phenyl)-cyclopropanecarboxylic acid[1-(2,3-dihydro-benzofuran-5-yl)-ethyl]-amide for example; for pain, migraine, neuropathic pain, bipolar disorders, convulsions, mania, epilepsy, anxiety, depression and neurodegenerative disorders | KCNQ2, KCNQ5, KCNJ2 | GABRB1 133/4885GABRB2 140/4885GPR88 604/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.